|
Showing 1 - 2 of
2 matches in All Departments
This issue of Medical Clinics of North America brings the physician
up to date on the newest agents for antibacterial therapy.? New
drugs are covered, as well as new approaches.? Topics include the
newer fluoroquinolones; epidemiology, molecular mechanisms, and
clinical management of pathogens resistant to antibacterial agents;
current use for old antibacterial agents, including polymyxins,
rifamycins, and aminoglycosides; topical antibacterial agents;
newer beta-lactam antibiotics, including doripenem, ceftobiprole.
ceftaroline, and cefepim; the use of antibacterial agents in renal
failure; antibiotics for gram positive bacterial infections,
including vancomycin, teicoplanin, quinupristin/dalfopristin,
oxazolidinolones, daptomycin, telavancin, and ceftaroline; as well
as macrolides, ketolides, and glycylcyclines, including
azithromycin, clarithromycin, telithromycin, and tigecycline.
Infectious diseases is a rapidly changing field in which new
organisms emerge, previously identified organisms develop
resistance to treatment, and infections that had previously almost
disappeared become resurgent. These factors require rapid changes
in therapeutic approaches, especially in the use of antimicrobial
agents. This issue covers antibiotics in specific populations
(children, the elderly, and patients with renal failure),
antimicrobial resistance, and new drugs in several classes,
including macrolides, fluoroquinolones, beta-lactam antibiotics,
and agents for gram-positive infections.
|
|